Dr. Kevin Dalby (@KevinNDalby) is the Johnson & Johnson Centennial Professor of chemical biology and medicinal chemistry in the College of Pharmacy, and Department of Oncology at The University of Texas in Austin. Dr. Dalby is the author of more than 100 publications on the molecular basis of protein kinase regulation and cancer-related drug discovery research. Dr. Dalby directs the overall operations of TTP.
The Dalby laboratory is developing a small molecule screening program to identify strategies and lead compounds to address the current COVID-19 pandemic as well as future coronavirus outbreaks. These screens target multiple critical elements of a coronavirus infection cycle, including its ability to enter host cells, to replicate within the host, and to avoid the host’s immune surveillance. These screens make possible the implementation of strategies to target both host and viral proteins using FDA-approved drugs, drugs in pre-clinical development, as well as many thousands of in-house test compounds. While tremendous effort is underway to develop vaccines for the current pandemic, this development faces enormous challenges and will likely not address future epidemics. It is critical for the future health and economic security of the US to develop a suite of candidate drugs for future pandemics.